Request Demo

Last update 08 May 2025

Anti-mesothelin CAR-T Cell Therapy (Pell Bio-Med Technology)

Last update 08 May 2025

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

Drug Type

CAR-T

Synonyms

Anti-mesothelin chimeric antigen receptor T cell therapy (Pell Bio-Med Technology), CAR-NK cell therapy(Pell Bio-Med Technology), CAR-T/NK cell therapy

+ [1]

Target

MSLN

Action

inhibitors

Mechanism

MSLN inhibitors(Mesothelin inhibitors), Gene transference, T lymphocyte replacements

Therapeutic Areas

Neoplasms

Active Indication-

Inactive Indication

Neoplasms

Originator Organization

PELL Bio-Med Technology Co., Ltd.

Active Organization-

Inactive Organization

PELL Bio-Med Technology Co., Ltd.

License Organization-

Drug Highest PhaseDiscontinuedPreclinical

First Approval Date-

Regulation-

100 Clinical Results associated with Anti-mesothelin CAR-T Cell Therapy (Pell Bio-Med Technology)

100 Translational Medicine associated with Anti-mesothelin CAR-T Cell Therapy (Pell Bio-Med Technology)

100 Patents (Medical) associated with Anti-mesothelin CAR-T Cell Therapy (Pell Bio-Med Technology)

Literatures (Medical) associated with Anti-mesothelin CAR-T Cell Therapy (Pell Bio-Med Technology)

01 Apr 2025·Molecular Therapy

Turning “trashed” genomic loci into treasurable sites for integrating chimeric antigen receptors in T and NK cells

Review

Author: Xu, Xiaobao ; Sun, Jie ; Shang, Kai ; Jiang, Jie ; Wang, Yajie

Chimeric antigen receptor (CAR)-based immune cell therapy involves genetically engineering immune cells, such as T cells and natural killer (NK) cells, to express CARs that can specifically recognize target antigens. This modification enables T/NK cells to selectively eliminate tumor cells following adoptive transfer. One common approach to stably integrate CARs into the genome of T/NK cells is through retroviral or lentiviral vectors. However, these vectors mediate semi-random gene integration, posing risks such as oncogenic mutations, gene silencing, and variable CAR expression levels. Targeted integration of CAR genes into the specific genomic locus could overcome these limitations, but identifying the optimal integration sites to maximize the safety and efficacy of CAR-T/NK cell products remains a critical question. Improper integration sites may disturb the endogenous genes surrounding the integration sites, raising safety concerns. Additionally, regulatory elements at the integration sites, such as promoters, can influence the expression level of CAR genes, thus affecting the efficacy of CAR-T/NK cells. In this review, we summarized current strategies for selecting integration sites and promoters in the engineering of CAR-T/NK cells to achieve potent anti-tumor efficacy in preclinical studies.

01 Sep 2024·Expert Opinion on Therapeutic Targets

Looking ahead to targeting macrophages by CAR T- or NK-cells in blood cancers

Review

Author: Tigu, Adrian-Bogdan ; Daniela Tănase, Alina ; Einsele, Hermann ; Tomai, Radu ; Milea, Paul Alexandru ; Kegyes, David ; Nistor, Madalina ; Cenariu, Diana ; Mazga, Andreea-Isabella ; Tomuleasa, Ciprian ; Buruiana, Sanda

INTRODUCTIONThe bone marrow microenvironment (BME) is critical for healthy hematopoiesis and is often disrupted in hematologic malignancies. Tumor-associated macrophages (TAMs) are a major cell type in the tumor microenvironment (TME) and play a significant role in tumor growth and progression. Targeting TAMs and modulating their polarization is a promising strategy for cancer therapy.AREAS COVEREDIn this review, we discuss the importance of TME and different multiple possible targets to modulate immunosuppressive TAMs such as: CD123, Sphingosine 1-Phosphate Receptors, CD19/CD1d, CCR4/CCL22, CSF1R (CD115), CD24, CD40, B7 family proteins, MARCO, CD47, CD163, CD204, CD206 and folate receptors.EXPERT OPINIONInnovative approaches to combat the immunosuppressive milieu of the tumor microenvironment in hematologic malignancies are of high clinical significance and may lead to increased survival, improved quality of life, and decreased toxicity of cancer therapies. Standard procedures will likely involve a combination of CAR T/NK-cell therapies with other treatments, leading to more comprehensive cancer care.

04 Jul 2023·Biomarker research

Site-specific transgene integration in chimeric antigen receptor (CAR) T cell therapies.

Review

Author: Habibi Anbouhi, Mahdi ; Dabiri, Hamed ; Basiri, Mohsen ; Safarzadeh Kozani, Pooria ; Hajizadeh Saffar, Ensiyeh ; Haddadi, Mohammad Hossein ; Sadeghizadeh, Majid ; Ziaei, Vahab ; Mirzaee Godarzee, Mohadeseh

Chimeric antigen receptor (CAR) T cells and natural killer (NK) cells are genetically engineered immune cells that can detect target antigens on the surface of target cells and eliminate them following adoptive transfer. Recent progress in CAR-based therapies has led to outstanding clinical success in certain patients with leukemias and lymphomas and offered therapeutic benefits to those resistant to conventional therapies. The universal approach to stable CAR transgene delivery into the T/NK cells is the use of viral particles. Such approaches mediate semi-random transgene insertions spanning the entire genome with a high preference for integration into sites surrounding highly-expressed genes and active loci. Regardless of the variable CAR expression level based on the integration site of the CAR transgene, foreign integrated DNA fragments may affect the neighboring endogenous genes and chromatin structure and potentially change a transduced T/NK cell behavior and function or even favor cellular transformation. In contrast, site-specific integration of CAR constructs using recent genome-editing technologies could overcome the limitations and disadvantages of universal random gene integration. Herein, we explain random and site-specific integration of CAR transgenes in CAR-T/NK cell therapies. Also, we tend to summarize the methods for site-specific integration as well as the clinical outcomes of certain gene disruptions or enhancements due to CAR transgene integration. Also, the advantages and limitations of using site-specific integration methods are discussed in this review. Ultimately, we will introduce the genomic safe harbor (GSH) standards and suggest some appropriate safety prospects for CAR integration in CAR-T/NK cell therapies.

100 Deals associated with Anti-mesothelin CAR-T Cell Therapy (Pell Bio-Med Technology)

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Neoplasms	Preclinical	Taiwan Province	PELL Bio-Med Technology Co., Ltd.	21 Apr 2022

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis


No Data

Anti-mesothelin CAR-T Cell Therapy (Pell Bio-Med Technology)

Overview

Basic Info

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation